Teneobio and Selexis Enter Second Services Agreement to Develop Research Cell Banks as Teneobio Prepares to Advance Three Additional Oncology-Targeting Multi-Specific UniAbs into the Clinic

GENEVA & MENLO PARK, Calif. — (BUSINESS WIRE) — Selexis SA and Teneobio, Inc. announced today that they have entered into a second services agreement to expand Teneobio’s oncology pipeline of Human Heavy-Chain Antibodies (UniAbs®), a new class of multi-specific biologics.
Read more

Teneobio and Poseida Expand Their Partnership to Develop UniDabs® for Advanced CAR-T Therapies

MENLO PARK, Calif. and SAN DIEGO, Aug. 07, 2018 (GLOBE NEWSWIRE) — Teneobio, Inc., a next generation multi-specific antibody therapeutics company, and Poseida Therapeutics, Inc., a San Diego-based clinical-stage company translating best-in-class gene engineering technologies into lifesaving cell therapies, announced today a new research collaboration and licensing agreement to develop novel CAR-T therapies using Teneobio’s heavy chain only domain antibodies (UniDabs®).
Read more

Teneobio Announces Research Collaboration with Janssen to Develop Multispecific Antibodies for Oncology

MENLO PARK, Calif., July 09, 2018 (GLOBE NEWSWIRE) — Teneobio, Inc., a next generation multi-specific antibody therapeutics company, announced today the initiation of a research collaboration and licensing agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop novel multi-specific antibodies for undisclosed oncology targets.
Read more

Teneobio Announces a Strategic Alliance with TESARO to Develop the Next Generation of Immuno-Oncology, Multispecific Antibodies

MENLO PARK, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) — Teneobio, Inc., a next generation multi-specific antibody therapeutics company announced today the initiation of a research collaboration and licensing agreement with TESARO, Inc., an oncology-focused biopharmaceutical company, to develop novel multi-specific antibodies for up to six undisclosed oncology targets.
Read more

Selexis SA and TeneoBio, Inc. Team Up to Advance the Development of UniAbs Targeting Cancer

GENEVA & MENLO PARK, Calif.– (BUSINESS WIRE) — Selexis SA and TeneoBio, Inc. announced today that they have entered into a service agreement to advance the development of a new class of biologics, Human Heavy-Chain Antibodies (UniAbs®) targeting cancer.
Read more